Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Targeting Bladder Carcinoma in Situ With Novel Gene Therapy

By: Lauren Harrison, MS
Posted: Wednesday, November 18, 2020

The use of a novel intravescial gene-mediated therapy, nadofaragene firadenovec, seemed to demonstrate activity in patients with Bacillus Calmette-Guerin (BCG)-unresponsive carcinoma in situ of the bladder. Nadofaragene firadenovec works through delivering the human interferon alpha-2b gene, leading to an increase in expression of interferon alpha-2b. This work was published in the Journal of Clinical Oncology by Stephen A. Boorjian, MD, of Mayo Clinic in Rochester, Minnesota, and colleagues.

“These data represent a potentially significant management advancement for a historically difficult-to-treat disease state,” concluded the authors.

This phase III, open-label, multicenter trial enrolled 157 patients with high-grade non–muscle-invasive bladder cancer (carcinoma in situ and/or Ta/T1 disease) that was unresponsive to BCG. Patients received 75 mL of 3 x 1011 vp/mL of nadofaragene firadenovec once every 3 months for up to four doses in the first year of therapy. Additional dosing was administered at the investigator’s discretion.

A total of 103 patients had carcinoma in situ of the bladder, and 53.4% of these patients achieved a complete response to therapy. These responses were all seen by month 3 after treatment. Within this group of complete responders, 45.5% remained free of high-grade recurrence at month 12, as confirmed by biopsy. Among the patients with high-grade Ta/T1 disease alone, 72.9% did not have recurrence at 3 months, and 43.8% were recurrence-free at 12 months.

Treatment-emergent adverse events were generally transient among this cohort. They included instillation-site discharge (33.1%), fatigue (23.6%), bladder spasm (19.7%), micturition urgency (17.8%), and hematuria (16.6%). Two grade 4 adverse events were reported, including sepsis and an anaphylactic reaction, which were not related to the study drug. There were no grade 5 adverse events observed.

Disclosure: For a full list of authors’ disclosures, visit coi.asco.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.